Results 161 to 170 of about 5,687 (195)
Some of the next articles are maybe not open access.
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib [PDF]
Blood Advances, 2019 The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation.
Farrukh T Awan +2 more
exaly +2 more sources
Acalabrutinib: First Global Approval
Drugs, 2017Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and ...
Anthony, Markham, Sohita, Dhillon
openaire +2 more sources
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant (ASCT) in combination with bendamustine and rituximab (BR), if certain conditions are met.
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant (ASCT) in combination with bendamustine and rituximab (BR), if certain conditions are met.
openaire +1 more source